Nasdaq rxrx.

There are a couple of particularly risky stocks that AI investors have been gravitating toward this year that you're better off avoiding. Recursion Pharmaceuticals ( RXRX 8.83%) and C3.ai ( AI 6. ...December 9, 2023 at 11:06 AM · 4 min read. In a notable insider transaction, CEO Christopher Gibson sold 59,829 shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) on December 6, 2023. This ...Find the latest on short interest for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. AMD. Advanced Micro Devices, Inc. Common Stock. $177.25 -3.08 -1.71%. Get the latest updates on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) after hours trades, after hours share ... Jan 21, 2024 · Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,335,132 shares of the compa

2 days ago · Mirae Asset Global Investments Co. Ltd. increased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 31.0% in the 3rd quarter, according to the company in ... 1 day ago · The Nasdaq Composite rose like a phoenix from the ashes in 2023, but history suggests there's more growth to come. Generative AI kick-started the market last year, but it's still early innings for ...

Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment... November 10, 2023 at 5:06 AM · 3 min read. With a price-to-sales (or "P/S") ratio of 23.8x Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX) may be sending very bearish signals at the moment, given ...

N/A Dividend Yield N/A Price Target $11.20 Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings …Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1.9% on Insider Selling marketbeat.com - December 29 at 10:20 AM: Blake Borgeson Sells 20,054 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock marketbeat.com - December 28 at 6:33 PMJan 19, 2024 · A. The latest price target for Recursion Pharmaceuticals ( NASDAQ: RXRX) was reported by Needham on Wednesday, January 17, 2024. The analyst firm set a price target for 15.00 expecting RXRX to ... Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the latest acquisitions of Harvard Management Company as the fund bought over 1.5 million shares of the company worth $55.08 million in Q2 2021.Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel ...

The Nasdaq Composite rose like a phoenix from the ashes in 2023, but history suggests there's more growth to come. Generative AI kick-started the market last …

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical stage biotechnology company that combines the disciplines of biology, chemistry, data analytics, and engineering to develop drugs.

Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance.According to the issued ratings of 4 analysts in the last year, the consensus rating for Recursion Pharmaceuticals stock is Hold based on the current 3 hold ratings and 1 buy rating for RXRX. The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of $8.00. AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed …With Recursion Pharmaceuticals stock trading at $11.93 per share, the total value of Recursion Pharmaceuticals stock (market capitalization) is $2.58B. Recursion Pharmaceuticals stock was originally listed at a price of $31.30 in Apr 16, 2021. If you had invested in Recursion Pharmaceuticals stock at $31.30, your return over the last 2 years ...Data is delayed at least 15 minutes. Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the …See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

This is an increase of 9 owner (s) or 2.75% in the last quarter. Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 14.38%. Total shares owned by institutions ...Nov 26, 2023 · For a biotech like Recursion Pharmaceuticals (RXRX-2.63%) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ... Nov 15, 2023 · AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ... For a biotech like Recursion Pharmaceuticals (RXRX-1.25%) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ...December 29, 2023. Shares of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX - Get Free Report) dropped 1.9% on Friday following insider selling activity. The stock traded as low as $10.41 and last traded at $10.41. Approximately 154,367 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 3,473,452 …Welcome to Recursion: The Future of TechBio. LEARN HOW ›. NEWS: Recursion unveils LOWE, an LLM-Orchestrated Workflow Engine for drug discovery. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company.

The firm has a market cap of $2.09 billion, a PE ratio of -6.60 and a beta of 0.63. Recursion Pharmaceuticals ( NASDAQ:RXRX – Get Free Report) last announced its earnings results on Thursday ...

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion Pharma (NASDAQ: RXRX) made waves this week.On Wednesday, the firm reported a hefty $50 million cash infusion from Nvidia to support efforts in developing AI models that speed up drug ...About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...The stock price for . Recursion Pharmaceuticals (NASDAQ: RXRX) is $9.98 last updated Today at January 18, 2024 at 7:59 PM EST. Q Does Recursion …Recursion Pharmaceuticals (NASDAQ: RXRX) leverages AI and machine learning to revolutionize the discovery of drug candidates. They analyze vast amounts of biological and imaging data from assays, ...Jan 19, 2024 · Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is the latest addition in Srini Akkaraju and Michael Dybbs’ hedge fund portfolio, as Samsara BioCapital bought 775,583 shares worth $28.31 million ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...

Jan 4, 2024 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel ...Recursion Pharmaceuticals (NASDAQ:RXRX) is one of the high-flying stocks gaining focus in today’s market. Indeed, shares of RXRX stock are rocketing more than 10% higher today on some rather ...REC-2282 is developed for the treatment of neurofibromatosis type 2. paper trading platform. Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain data, and a fully built financial calendar to help you invest smart.The budgetary allocation to AI and machine learning in healthcare is expected to reach 10.5% in 2024, up from 5.5% in 2022, Morgan Stanley says. Read more here.December 29, 2023. Shares of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX - Get Free Report) dropped 1.9% on Friday following insider selling activity. The stock traded as low as $10.41 and last traded at $10.41. Approximately 154,367 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 3,473,452 …Clinical-stage biotech company Recursion Pharmaceuticals (NASDAQ:RXRX) might be a relatively small company, but it’s taking significant steps toward a stronger future. Wall Street currently ...Recursion Pharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View RXRX financial statements in full.Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the latest acquisitions of Harvard Management Company as the fund bought over 1.5 million shares of the company worth $55.08 million in Q2 2021.Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.

Recursion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RXRX updated stock price target summary.Recursion Pharmaceuticals Stock Down 2.6 %. Shares of NASDAQ RXRX opened at $9.63 on Monday. The business has a 50-day simple moving average of $8.96 and a two-hundred day simple moving average of ...Shares of Recursion Pharmaceuticals ( NASDAQ: RXRX) climbed on Thursday after the AI-led biotech announced a licensing agreement with German conglomerate Bayer ( OTCPK:BAYZF) to in-license a new ...Recursion Pharmaceuticals: More Hype Than Substance (NASDAQ:RXRX) | Seeking Alpha Join the community. Try Seeking Alpha for free by creating an account» …Instagram:https://instagram. first time supervisor checklistuta rn bsnandersen windows at lowepercent27s3150be684e6692495f33c5952964b386777b16c8 250x250.jpeg All Rights Reserved. Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global …Oct 14, 2021 · The big shareholder groups in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see ... 5ad3ezzz Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year il font l Key statistics. On Friday, Recursion Pharmaceuticals Inc (RXRX:NSQ) closed at 11.16, -33.35% below its 52-week high of 16.75, set on Jul 19, 2023. Data delayed at least 15 minutes, as of Jan 12 2024 21:00 GMT. Latest Recursion Pharmaceuticals Inc (RXRX:NSQ) share price with interactive charts, historical prices, comparative analysis, …So should Recursion Pharmaceuticals (NASDAQ:RXRX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of ...